Orthofix Medical (NASDAQ:OFIX) Stock: Insider Juniper Investment Company, Ll Acquires 675,000 Shares

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Juniper Investment Company, Ll acquired 675,000 shares of Orthofix Medical stock in a transaction that occurred on Monday, November 9th. The shares were bought at an average cost of $7.41 per share, with a total value of $5,001,750.00. Following the transaction, the insider owned 4,446,216 shares in the company, valued at $32,946,460.56. This represents a 17.90% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Juniper Investment Company, Ll also recently made the following trade(s):

• On Wednesday, November 11th, Juniper Investment Company, Ll acquired 14,803 shares of Orthofix Medical stock. The shares were purchased at an average cost of $7.04 per share, for a total transaction of $104,213.12.

Orthofix Medical Trading Up 3.3%

Shares of NASDAQ OFIX opened at $7.17 on Friday. The company has a market cap of $292.03 million, a PE ratio of -6.40 and a beta of 0.66. Orthofix Medical Inc. has a 52-week low of $6.52 and a 52-week high of $16.42. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.67 and a current ratio of 3.11. The firm’s 50 day moving average price is $9.07 and its 200-day moving average price is $10.83.

Orthofix Medical (NASDAQ:OFIX) last issued its earnings results on Monday, November 9th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. Orthofix Medical had a negative net margin of 5.39% and a negative return on equity of 10.32%. The company had revenue of $207.86 million for the quarter, compared to analysts’ expectations of $210.52 million. On average, equities research analysts expect that Orthofix Medical Inc. will post -1.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. TD Cowen restated a “hold” rating and set a $9.00 price objective on shares of Orthofix Medical in a research report on Tuesday. Canaccord Genuity Group reduced their price target on shares of Orthofix Medical from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Finally, Weiss Ratings downgraded Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Orthofix Medical currently has an average rating of “Hold” and an average price target of $13.50.

Institutional Trading of Orthofix Medical

Several institutional investors and hedge funds have recently made changes to their positions in OFIX. Parallel Advisors LLC raised its holdings in shares of Orthofix Medical by 2,434.1% in the 3rd quarter. Parallel Advisors LLC now owns 3,269 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 3,140 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new position in Orthofix Medical in the 2nd quarter worth approximately $30,000. Legal & General Group Plc acquired a new stake in Orthofix Medical during the second quarter worth about $37,000. Vise Technologies Inc. purchased a new position in shares of Orthofix Medical during the 3rd quarter valued at approximately $96,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Orthofix Medical during the 2nd quarter worth about $114,000. 89.76% of the stock is currently owned by institutional investors.

Orthofix Medical Company Profile

Orthofix Medical Inc. develops and markets medical technologies for spine and orthopedic care. Its products include spinal implants and biologics, bone growth stimulation systems, and solutions used in fracture treatment and limb reconstruction. The company serves hospitals, surgeons, and other health care providers through its Orthofix and SeaSpine businesses. Its offerings span surgical products as well as noninvasive and specialized orthopedic treatments. Orthofix and SeaSpine completed a merger in 2023, combining their spine and orthopedic product portfolios.